Log in

NYSE:ARPOAerpio Pharmaceuticals Stock Price, Forecast & News

-0.02 (-1.56 %)
(As of 07/3/2020 04:00 PM ET)
Today's Range
Now: $1.26
50-Day Range
MA: $1.09
52-Week Range
Now: $1.26
Volume676,894 shs
Average Volume1.24 million shs
Market Capitalization$51.14 million
P/E RatioN/A
Dividend YieldN/A
Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for ocular diseases. The company's lead product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a single ascending dose clinical trial for the treatment of inflammatory bowel disease. The company is headquartered in Cincinnati, Ohio. Aerpio Pharmaceuticals, Inc.(OTCPK:ARPO) operates independently of Akebia Therapeutics, Inc. as of December 22, 2011.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.42 out of 5 stars

Industry, Sector and Symbol

Industry Biotechnology



Sales & Book Value

Annual SalesN/A



Market Cap$51.14 million
Next Earnings Date8/13/2020 (Estimated)
OptionableNot Optionable

Receive ARPO News and Ratings via Email

Sign-up to receive the latest news and ratings for ARPO and its competitors with MarketBeat's FREE daily newsletter.

Aerpio Pharmaceuticals (NYSE:ARPO) Frequently Asked Questions

How has Aerpio Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Aerpio Pharmaceuticals' stock was trading at $0.54 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ARPO stock has increased by 133.3% and is now trading at $1.26. View which stocks have been most impacted by Coronavirus.

When is Aerpio Pharmaceuticals' next earnings date?

Aerpio Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Aerpio Pharmaceuticals.

How were Aerpio Pharmaceuticals' earnings last quarter?

Aerpio Pharmaceuticals, Inc. (NYSE:ARPO) released its earnings results on Thursday, May, 7th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.09) by $0.01. View Aerpio Pharmaceuticals' earnings history.

Has Aerpio Pharmaceuticals been receiving favorable news coverage?

News articles about ARPO stock have trended negative this week, according to InfoTrie Sentiment. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Aerpio Pharmaceuticals earned a media sentiment score of -2.8 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 7.0 out of 10, meaning that recent press coverage is likely to have an impact on the stock's share price in the immediate future. View the latest news about Aerpio Pharmaceuticals.

Who are some of Aerpio Pharmaceuticals' key competitors?

What other stocks do shareholders of Aerpio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aerpio Pharmaceuticals investors own include SCYNEXIS (SCYX), Innovative Industrial Properties (IIPR), The Ensign Group (ENSG), MYR Group (MYRG), Acasti Pharma (ACST), Aphria (APHA), Avid Technology (AVID), JAKKS Pacific (JAKK), JPMorgan Chase & Co. (JPM) and Neurometrix (NURO).

Who are Aerpio Pharmaceuticals' key executives?

Aerpio Pharmaceuticals' management team includes the following people:
  • Dr. Stephen J. Hoffman, CEO & Director (Age 65)
  • Dr. Joseph H. Gardner, Founder, Pres & Director (Age 63)
  • Mr. Michael W. Rogers, Chief Financial Officer (Age 59)
  • Dr. Stephen Pakola, Chief Medical Officer (Age 50)
  • Mr. Kevin G. Peters, Chief Scientific Officer (Age 62)

What is Aerpio Pharmaceuticals' stock symbol?

Aerpio Pharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "ARPO."

How do I buy shares of Aerpio Pharmaceuticals?

Shares of ARPO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aerpio Pharmaceuticals' stock price today?

One share of ARPO stock can currently be purchased for approximately $1.26.

How big of a company is Aerpio Pharmaceuticals?

Aerpio Pharmaceuticals has a market capitalization of $51.14 million.

What is Aerpio Pharmaceuticals' official website?

The official website for Aerpio Pharmaceuticals is www.aerpio.com.

How can I contact Aerpio Pharmaceuticals?

The company can be reached via phone at 513-985-1920.

This page was last updated on 7/4/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.